Roche Introduces Three Factor Xa Coagulation Assessments Across Europe

Roche has introduced three coagulation assays for three oral Factor Xa inhibitors—specifically, apixaban, edoxaban, and rivaroxaban—in European nations that acknowledge the CE mark.  

Factor Xa inhibitors are treatments that prevent excessive blood clotting, and coagulation tests help doctors keep track of how efficient these treatments are.  

Factor Xa inhibitors typically do not require coagulation testing, however, in more severe cases such as emergency operations, overdosing, or blood clot blockages.  

The medications are used for a range of heart-related conditions, including coronary artery disease and non-valvular atrial fibrillation.  

Roche’s coagulation assays can be employed to evaluate the anti-Xa effectiveness of the three Factor Xa inhibitors, in addition to the anticoagulant heparin. 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.